East Asia Liver AllianceSCIENTIFIC PROGRAM

  • 13:00-13:10

  • Opening

    Young-Suk Lim (KASL), Tetsuo Takehara (JSH), Ming-Lung Yu (TASL)

13:10-14:10

SESSION 1. Building the EALA Consensus

Young-Suk Lim (Univ. of Ulsan, Korea), Ming-Lung Yu (Kaohsiung Medical Univ., Taiwan)

  • 13:10-13:30

  • Chronic Hepatitis B

    In Hee Kim (Jeonbuk National Univ., Korea)

  • 13:30-13:50

  • Evidence-Based Clinical Practice Guidelines for MASLD 2026

    Norio Akuta (Toranomon Hospital, Japan)

  • 13:50-14:10

  • Surveillance of HCC, Current Status and Future Directions in Taiwan

    Sheng-Nan Lu (Jen Ai Hospital, Taiwan)

  • 14:10-14:30

  • Break, Group Photos

14:30-15:30

SESSION 2. Outstanding Research from EALA: MASLD

Tetsuo Takehara (The Univ. of Osaka, Japan), Chung-Feng Huang (Kaohsiung Medical Univ., Taiwan)

  • 14:30-14:50

  • Sex-Specific Cardiometabolic Risk Factors and Histological Predictors of MASLD Outcomes: Evidence from Japanese Multicenter Cohorts

    Tsubasa Tsutsumi (Kurume Univ., Japan)

  • 14:50-15:10

  • Emerging Trends and Multifaceted Risk Interactions of MASLD: Perspectives from Taiwan Cohorts

    Ming-Lun Yeh (Kaohsiung Medical Univ., Taiwan)

  • 15:10-15:30

  • Efficacy and Safety of Time-Restricted Eating in MASLD

    Joo Hyun Oh (CHA Univ., Korea)

14:30-15:30

SESSION 3. Outstanding Research from EALA: HCC

Si Hyun Bae (The Catholic Univ. of Korea, Korea), Tatsuya Kanto (Japan Institute for Health Security, Japan)

  • 15:30-15:50

  • Bystander CD8⁺ T Cells in Hepatocellular Carcinoma

    Chun-Yen Lin (Chang Gung Univ., Taiwan)

  • 15:50-16:10

  • Developing and Validating a Risk Prediction Model in HCC Patients on Atezolizumab–Bevacizumab

    Heechul Nam (The Catholic Univ. of Korea, Korea)

  • 16:10-16:30

  • Biomarker Discovery of Combination Immunotherapy for HCC

    Takahiro Kodama (The Univ. of Osaka, Japan)

  • 16:30-16:40

  • Closing Remarks

    Ji Hoon Kim (Korea Univ., Korea)